Moderna Inc.’s Covid Vaccine. generated more than double the antibodies of a comparable injection made by Pfizer Inc. and BioNTech SE in research directly comparing immune responses to the inoculations.
A study of nearly 2,500 workers in a large Belgian hospital system found antibody levels in individuals who were not infected with the coronavirus before receiving two doses of the Moderna vaccine averaged 2,881 units per milliliter, compared with 1,108 units/ml in an equivalent group that received two doses of the Moderna vaccine. got two shots from the Pfizer shot.
The results, published Monday in a letter to the Journal of the American Medical Association, suggested the differences could be explained by:
– higher amount of active ingredient in the Moderna vaccine – 100 micrograms, versus 30 micrograms in Pfizer-BioNTech
– longer interval between doses of Moderna vaccine – four weeks, versus three weeks for Pfizer-BioNTech
Moderna’s vaccine was associated with a twofold risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizer’s in a human assessment at the Mayo Clinic Health System in the US from January to July. The results were reported in a separate study released Aug. 9 ahead of publication and peer review.